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Statement of the problem:  Literature suggests that the incidence of and outcomes following 
Acute Respiratory Distress Syndrome (ARDS) vary with the presence of certain chronic 
comorbidities, possibly due to alterations in the innate immune system.  We sought to determine 
whether the association of lung-protective ventilation (LPV), defined by tidal volumes ≤6.5 ml/ 
kg predicted body weight and plateau pressures ≤30 cm H2O, with ICU survival was modified by 
the presence of certain comorbidities. 
Methods:  Multi-variable, time-varying Cox regression analysis of a multisite, prospective cohort 
study of 485 patients with baseline assessment of seven comorbidities potentially associated with 
ARDS progression.  Analyses included adjustment for twice-daily assessment of tidal volume and 
other respiratory variables and daily assessment of other mortality predictors.  Effect modification 
between the effect of LPV and each of seven comorbidities was assessed by a statistical 
interaction term. 
Results:  The prevalence of comorbidities was as follows:  119 (25%) had excess alcohol use 
histories, 112 (23%) diabetes, 69 (14%) HIV disease, 51 (11%) injection drug use within past 30 
days, 48 (9.9%) moderate or severe liver disease, 42 (8.7%) hematologic malignancy history, and 
36 (7.4%) rheumatologic disease.  The adjusted hazard ratio (HR) for mortality for each 12-hour 
period of LPV-ventilation was 0.96 (95% CI:  0.93-1.00; p=0.041).  Only hematologic 
malignancy demonstrated a significant interaction (p=0.039 for interaction) with LPV, with HRs 
for each 12-hour period with LPV in patients with vs. without this comorbidity of 1.03 (95% CI 
0.94-1.12) and 0.96 (95% CI 0.93-1.00), respectively.   
Conclusions:  There was limited support for the hypothesis that LPV’s protective effect may be 
modified by the presence or absence of certain comorbidities present before ARDS onset.  Of 
seven comorbidities tested only a history of hematologic malignancy demonstrated a significant 
interaction with the effect of LPV adherence, with LPV having no protective effect in patients 
with this comorbidity. 
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Introduction 
Acute respiratory distress syndrome (ARDS) is a common and often lethal disease process in the 
intensive care unit (ICU).  ARDS generally occurs shortly after an inciting acute event, such as 
trauma, pulmonary- or non-pulmonary sepsis, or pancreatitis.1  The “two-hit hypothesis” of 
ARDS pathophysiology2,3 proposes that ARDS develops as the result of a second mechanical, 
chemical, or biological insult to the lung in the setting of an already vulnerable host inflammatory 
milieu.  For example, ARDS may develop during mechanical ventilation following severe trauma 
at a site distant from the lung or following a unilateral pneumonia. Lung injury may be initiated 
primarily by innate immune system pathways via pattern recognition receptors (PRRs) directed 
either toward foreign structures (referred to as pathogen-associated molecular patterns (PAMPs)), 
such as bacterial lipopolysaccharide, or to intrinsic markers of cell damage (referred to as 
damage-associated molecular patterns (DAMPs)), such as native high-mobility group box 1 
protein.4,5  PRR activation then stimulates toll-like receptor (TLR) pathways in macrophages and 
other sentinel immune cells contributing to further inflammation and multi-organ failure.4,5 
Certain chronic diseases may alter a patient’s risk for developing ARDS following an inciting 
acute insult and/or their likelihood of then surviving subsequent ARDS.6  In most of these chronic 
disease states, the biochemical mechanisms underlying these observations are poorly understood.  
However, chronic alcohol abuse is a relatively well-described model of how a pre-existing 
comorbidity might influence ARDS progression.  Chronic alcohol abuse is known to increase the 
risk for developing ARDS7 and the absolute risk of death after ARDS onset8,9 by altering the 
redox state of cells via alterations in glutathione and free-radical metabolism thus making the 
cells more susceptible to inflammatory injury.10,11  Other chronic disease states also have shown 
increased risk for developing ARDS and/or increased risk-adjusted mortality after ARDS onset, 
including HIV disease,12-14 hepatic cirrhosis,12, 15-18 injection drug abuse,19 auto-immune 
diseases20-23 and some cancers.24,25 
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Conversely, diabetes appears to reduce the risk-adjusted odds of developing ARDS.25-28 The 
differing impacts of some chronic diseases on ARDS risk has been hypothesized to result from 
known differences in macrophage expression of the PPAR-gamma and heme-oxygenase-1 
pathways in different chronic inflammatory states.29,30   
Patients with ARDS usually require mechanical ventilatory support.  Traditionally, this was done 
using relatively large tidal volumes and low positive end-expiratory pressures (PEEP).  This 
approach leads to mechanical ventilation-induced barotrauma, atelectatrauma, and biotrauma.31-34  
Subsequent randomized controlled trials and meta-analyses of ARDS have demonstrated that a 
volume- and pressure-limited lung protective mechanical ventilation (LPV) strategy, with 
algorithmically-titrated PEEP, reduces short-term mortality.35-39  Other studies have demonstrated 
release of DAMPs with mechanical ventilation40 and variations in inflammatory markers of 
ARDS with different mechanical ventilation strategies.41,42   Other researchers have reported 
reductions in inflammatory markers and neutrophil activity with an LPV strategy in both animal 
models43,44 and patients with ARDS.45  These observations suggest that LPV may act, at least 
partly, by modifying the underlying immunologic processes that initiate and propagate ARDS. 
Given this evidence, we hypothesized that the association between LPV and short-term survival 
would differ according to a patient’s comorbid disease state prior to ARDS onset. 
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Methods 
 We enrolled 520 consecutive eligible patients with ARDS into an institutional review board 
(IRB)-approved prospective cohort study conducted between 2004 and 2007.   These patients 
were being treated in 13 medical, trauma, and surgical ICUs at four Baltimore, Maryland 
academic medical centers.   For inclusion, patients were required to be mechanically ventilated 
and meet the American-European consensus criteria for acute lung injury.46  The American-
European consensus criteria were the diagnostic criteria in effect at the time of enrollment.  
Consistent with the more current Berlin consensus recommendations,47 we use the term ARDS 
rather than acute lung injury to describe this cohort.  IRB approval was obtained from all 
participating sites with a waiver of informed consent granted for abstraction of preexisting data 
from the medical record.  
Patients were ineligible for enrollment if they were managed in an ICU specializing primarily in 
neurologic diseases or were patients with acute lung injury with primary neurologic disease or 
head trauma.  Patients were also excluded from enrollment if they had a physician order limiting 
life support (other than a sole “do not resuscitate order”), life expectancy <6 months, baseline 
communication limitations or cognitive deficits, lacked a fixed follow-up address, were 
transferred from an outside facility with ALI duration > 24 hours, were mechanically ventilated > 
5 days prior to ALI development, or had history of lung resection.  Patients also were excluded 
from this analysis if they had  no “eligible” ventilator settings (as subsequently defined) or if they 
lacked a recorded height, both preventing assessment of adherence to LPV strategies. 
Assessment of lung protective ventilation (LPV) 
Mechanical ventilation settings and key ventilator measurements were recorded daily at 06:00 
and 18:00 for the duration of the patient’s mechanical ventilation.  A given ventilator setting was 
considered “eligible” for LPV if mechanical ventilation was provided via an artificial airway and 
if the FiO2 was either ≥ 50% or if the positive end expiratory pressure (PEEP) was >5 cm of 
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water.  We chose this definition because it approximated the threshold at which the ARDS 
Network ventilation protocol permitted trials of spontaneous breathing in which tidal volume and 
plateau pressure were not specified and discontinuation of mechanical ventilation could be 
evaluated.  A given ventilator setting was considered “adherent” to LPV if tidal volume was ≤ 6.5 
cc/ kg predicted body weight (PBW, the threshold used in the ARDS Network tidal volume trial 
to designate study site adherence to the goal tidal volume of ≤6.0 mL/kg PBW), and plateau 
pressure ≥30.  For patients in pressure-regulated modes, the plateau pressure was approximated 
using the peak pressure or the sum of the PEEP plus the prescribed increment in inspiratory 
pressure. 
All ventilator settings using airway pressure release ventilation (APRV) and high frequency 
oscillatory ventilation (HFOV) modes could not be assessed for adherence with LPV, but use of 
each of these two ventilator modes was considered in the analysis as time-varying covariates. 
Assessment of primary outcome:  survival during the initial ICU stay 
Survival until discharge from the index ICU admission for ARDS was selected as the primary 
outcome because of its temporal proximity to the primary exposure.  
Assessment of baseline comorbidities 
Baseline comorbidities were selected a priori, based on prior literature suggesting that their 
presence might alter the incidence of or death from ARDS.  These comorbidities, evaluated as 
effect-modifiers of the association of LPV and ICU survival, were:  HIV disease, excessive 
alcohol use, current injection drug use, moderate or severe liver disease, rheumatologic disease, 
prior or active hematologic malignancy, and diabetes.  These comorbidity data were obtain from 
medical records, with the Charlson comorbidity index definitions48 used to define HIV disease, 
moderate and severe liver disease, rheumatologic diseases, hematologic malignancy, and diabetes.  
Excess alcohol use was defined as current or prior alcoholism, alcohol abuse, problem drinking, 
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alcoholic cirrhosis, or alcoholic liver disease.  Current injection drug use was defined as injection 
or intravenous drug use within the past thirty days or specifically documented as “active" in the 
medical record.    
Assessment of baseline exposures 
Baseline exposures included patient characteristics and hospital admission diagnosis category, as 
obtained from medical records.  The following baseline exposures were included in the analyses:  
age, sex, body mass index (BMI) category, comorbidity burden (Charlson index),48 severity of 
illness within 24 hours of admission to the ICU (APACHE II score)49 and admission SOFA organ 
failure score,50 ARDS risk factor (non-pulmonary sepsis vs. all others), ICU type (medical vs. 
surgical), and ICU admission source (emergency department vs. all others).  Study site was also 
included in the model as a categorical variable.  Sites 3 and 4 were combined, as Site 4 had a 
small sample size and they shared ICU physician staffing patterns and had similar crude mortality 
hazard ratios. 
Assessment of time-varying covariates 
Time-varying covariates were collected once or twice daily beginning at ARDS onset and 
continuing for the duration of the patient’s mechanical ventilation and/ or ICU stay as 
appropriate.  Covariates measured once daily were: delirium status (Confusion Assessment 
Method for the ICU (CAM-ICU))51, sedation status (Richmond Agitation and Sedation Scale 
(RASS)),52 receipt and dose of systemic corticosteroids, and daily net fluid balance (total fluid 
input minus total fluid output).  Ventilation parameters included in the model, collected twice 
daily at 06:00 and 18:00, were: PaO2,  arterial pH, actual respiratory rate, static compliance of the 
respiratory system,  FiO2, positive end-expiratory pressure, and the use of APRV, HFOV, 
paralysis, or prone positioning during the preceding 12 hour period. 
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Missing data 
There were no patients with missing outcome or other patient-level data.  Less than 0.2% of the 
collected ventilator setting and arterial blood gas data was missing.  Approximately 10% of the 
plateau pressure values, required to calculate static compliance of the respiratory system, were 
missing, as were 16% of the RASS values and 25.7% of the CAM-ICU values.  Multiple 
imputation was used to impute each of these measurements, creating 5 complete datasets; Rubin’s 
method was used to pool the results across the imputed datasets.53,54    
Statistical analysis 
The key explanatory covariates were summarized and statistically compared using Fisher’s exact 
test or the non-parametric K-sample test of the equality of medians as appropriate. A 
multivariable time-varying Cox proportional hazards regression model was used to estimate the 
hazard ratios as a function of exposure to lung protective ventilation, the comorbidities of interest 
included in the model simultaneously, and the additional baseline exposures and time-varying 
covariates chosen a-prior for clinical relevance.  The primary exposure was modeled continuously 
as the time varying number of ventilator settings adherent to LPV with adjustment for the total 
duration of mechanical ventilation.  A robust (Huber-White sandwich) variance estimate was 
used.  The Efron method was used to handle ties.55,56  Within this multivariable time-varying Cox 
regression model including all of the comorbidity main-effects, statistical interactions between 
each of the binary indicators of the comorbidities  with the continuous LPV-adherence variable 
were separately assessed (i.e., a single comorbidity*LPV-adherence interaction term was present 
in the model).  The hazard ratios for the effect of LPV-adherence on survival in patients with and 
without the comorbidities were calculated. 
For continuous covariates, Martingale residual plots were created to confirm appropriate 
modeling, with no departures from linearity detected.  Variance inflation factor analysis 
confirmed no significant multicollinearity in the multivariable model.  The proportional hazard 
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assumption was tested using a test for trend and evaluation of graphical displays of Schoenfeld 
residuals. 
All statistical analyses were performed using STATA 13.1 (StataCorp, College Station, TX).  All 
tests of statistical significance used a two-sided P value <0.05. 
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Results 
Of the 520 patients enrolled in the study, 32 (6%) had no eligible ventilator settings and three 
(0.6%) had missing height and were excluded from analysis (Figure 1).  The remaining 485 
patients were on mechanical ventilation via an artificial airway during a total of 12,760 12-hour 
observation intervals.  Mechanical ventilation during 7112 (55.7%) of these intervals was eligible 
for LPV, and during 2548 (36%) of these intervals the ventilator settings were observed to be 
adherent to LPV.    
Among the 485 patients included in the analysis, the median (IQR) age was 53 (42-63) years, 
57% were male, and 38% were admitted from the Emergency Department (ED) (Table 1).   Most 
(85%) were admitted to a MICU, and 30% had non-pulmonary sepsis as the primary risk factor 
for ARDS (Table 1).  The median (IQR) baseline APACHE II was 27 (20-33).   
With respect to comorbidities, 25% of patients had a recorded history of alcohol abuse and 11% 
had abused drugs via injection within the past month. Only 6.2% were reported to have no 
chronic comorbidities (Table 2).   
In terms of ICU exposures (Table 3), the median (IQR) duration of mechanical ventilation 9 
(5-17) days, 24% of patients ever received neuromuscular blockade, 3.5% were ever proned, 13% 
were ever on APRV ventilation mode and 12% were ever on HFOV ventilation mode.  The 
median (IQR) ICU and hospital lengths of stay were 11 (6-18) and 21 (13-36) days, respectively.  
During their initial ICU stay 199 patients (41%) died.    
Table 4 presents the crude and adjusted hazard ratios for mortality during the index ICU 
admission as a function of LPV adherence, the comorbidities of interest and the remaining 
adjustment variables including duration of mechanical ventilation.   After adjustment for the 26 
explanatory covariates and LPV adherence, rheumatologic comorbid disease was significantly 
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associated with an increased hazard of ICU mortality (HR 2.65; 95% CI 1.40-5.02) (p = 0.003).  
Consistent with prior literature, the adjusted hazard of mortality was lower among patients with 
diabetes relative to those without  (HR 0.45; 95% CI 0.20-1.02) (p = 0.056); however, this result 
was not statistically significant.  The presence of HIV disease (HR 0.95; 95% CI 0.49-1.83) 
(p=0.876), current or prior excessive alcohol use (HR 0.96; 95% CI 0.59-1.55) (p=0.863), current 
injection drug use (HR 1.08; 95% CI 0.53-2.19) (p=0.827), hematologic malignancy (HR 0.77; 
95% CI 0.50-1.17) (p=0.217), or moderate or severe liver (HR 0.80; 95% CI 0.44-1.46) (p=0.474) 
did not confer a statistically significant increased adjusted hazard of ICU death. 
There was a non-significant statistical interaction (p=0.074) between the presence of 
rheumatologic disease and LPV-adherence (Table 5).  A history of hematologic malignancy 
demonstrated a statistically significant interaction (p = 0.039) with LPV adherence.  The hazard 
ratios for the effect of each 12-hour period with LPV-adherence (accounting for the main-effect 
term for LPV-adherence term plus the interaction between LPV-adherence and the presence or 
absence of hematologic malignancy) was higher in patients with (HR 1.03; 95% CI 0.94-1.12) 
versus without (HR 0.96; 95% CI 0.93-1.00) hematologic malignancy.
We were unable to detect any significant statistical interaction for the other comorbidities. 
However, patients with a history of excessive alcohol use, moderate or severe liver disease,  and 
diabetes all showed a non-significant increase in the summary protective effect of LPV-adherence 
(i.e., a reduction in the hazard ratio for death) when compared to patients without these 
comorbidities (Table 5).  Patients with HIV disease, current injection drug use, rheumatologic 
disease, or past or present hematologic malignancy did not demonstrate such an effect. 
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Discussion 
Pre-clinical and clinical research have implicated innate immune system signaling pathways as 
playing pivotal roles in the pathophysiology associated with the development and progression of 
ARDS and in the pathological mechanisms of ventilator-associated lung injury.4,5   It has also 
been suggested that activation of these pathways contribute to the increased morbidity and 
mortality associated with some chronic diseases in the setting of ARDS.30  In a multi-site, 485-
patient prospective cohort study of ARDS patients, we assessed the interaction between LPV and 
seven comorbidities that have been suggested in previous literature to modify the progression of 
ARDS, hypothesizing that the associations between LPV and short-term mortality would vary 
according to a patient’s comorbid disease state.  Our results provide limited data in support of this 
hypothesis.   
Our study found an adjusted HR of 0.96 (95% CI 0.93-1.00) for each additional 12 hour period of 
LPV-adherence.  Only one of the comorbidities, rheumatologic diseases (HR 2.65; 95% CI 
1.40-5.02), demonstrated an independent, increased hazard of death after adjusting for the other 
explanatory covariates.   
Hematologic malignancy was the only comorbidity that exhibited significant statistical interaction 
of the effect of LPV-adherence on the hazard of death (p=0.039).  However, among patients with 
excessive alcohol use, moderate or severe liver disease, or diabetes, the hazard ratios for each 
additional 12 hour period of LPV adherence demonstrated statistically significant reductions in 
the adjusted hazard of death, while among otherwise similar patients without these diseases no 
such protective effect was detected, with these differences not being statistically significant 
(Table 5).     
While we are unaware of any other literature that has attempted to assess for effect modification 
of LPV with comorbidities in ARDS, our findings are notable because excessive alcohol use, 
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moderate or severe liver disease, and diabetes are arguably the best-documented examples of 
chronic diseases which alter the incidence or natural history of ARDS.12,15-18,30 
Our study has potential limitations.  First, this was an observational study and therefore cannot 
prove causation. Second, our ability to assess for the presence and severity of comorbidities was 
limited by the use of medical records and existing definitions for their ascertainment.  This issue 
limited our ability to optimally assess for comorbidity activity (e.g., active hematologic 
malignancy vs. a remote history of it) and limited our ability to detect any true association that 
might exist.  Third,  the prevalence of some comorbidities within this cohort was low.  Moderate 
or severe liver disease, rheumatologic disease, and hematologic malignancy all occurred in <10% 
of our cohort.  This issue reduced our power to detect any true effect modification for these 
comorbidities.  Fourth, we also deliberately selected a proximal time point for our primary 
outcome (survival to ICU discharge).  While this reduced the likelihood that our results might be 
obscured by deaths not directly related to ARDS, it also reduced the observation time and number 
of deaths included in our survival analysis.  Finally, because our inclusion criteria required the 
presence of ARDS at enrollment, we are unable to make any inferences regarding associations 
between the comorbidities, LPV strategies, and ARDS incidence.   
Conclusion 
In this prospective cohort study of patients with ARDS, we found limited data to support our 
hypothesis that the association between LPV and short-term survival differed according to a 
patient’s comorbid disease state prior to ARDS onset.  Future studies attempting to assess for such 
an effect should consider evaluating larger cohorts of ARDS patients with higher prevalences of 
the comorbidities of interest and use robust methods for the ascertainment of the presence or 
absence of the relevant comorbidities.   
 11
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